MedPlus Inc.

The M&A Story Of The Year Casting an eye over our best-read lists, there was one story that clearly dominated Scrip ’s readers’ minds last year – Takeda Pharmaceutical Co. Ltd. ’s pursuit of Shire

Most buy-side funds are heavily invested in big-cap companies, some as much as 70%, because big-cap stocks offer solid growth, stability, and greater liquidity. The average biotech stock trades about

Becton Dickinson isn't known as a risk-taker and that's exactly what it is trying to be as it seeks to double its size in five years. By Wendy Diller Becton Dickinson & Co. 's huge factory in Canaa